Di-Methyl-Histone H3 (K10) Antibody

What is Di-Methyl-Histone H3 (K10) Antibody and what epigenetic modification does it detect?

Di-Methyl-Histone H3 (K10) antibody is a specialized research tool designed to recognize and bind specifically to histone H3 proteins that have been di-methylated at the lysine 10 (K10) position. According to product information, these antibodies are typically raised in rabbits and detect endogenous levels of histone H3 protein only when di-methylated at K10 .

This specificity is critical because histone modifications serve as epigenetic markers that regulate gene expression, DNA repair, and chromosomal stability. Different methylation states (mono-, di-, or tri-methylation) at specific lysine residues create a complex "histone code" that influences chromatin structure and DNA accessibility .

How does Di-Methyl-Histone H3 (K10) antibody differ from antibodies targeting K9 methylation?

While K10 and K9 methylation antibodies target adjacent lysine residues on histone H3, their specificities and biological implications differ significantly:

K9 methylation is more extensively studied and is recognized as a marker for heterochromatin and gene silencing, while the biological role of K10 methylation is still being investigated .

How can I validate the specificity of Di-Methyl-Histone H3 (K10) antibody?

Validating specificity is crucial for histone modification antibodies. A multi-method approach is recommended:

• Peptide array analysis: Test against synthetic peptides with various histone modifications to ensure recognition of only the intended mark .

• Dot blot analysis: Compare binding to peptides with different modifications at K10 and surrounding residues (mono-, di-, and tri-methylation) .

• Western blot with controls: Include samples treated with methyltransferase inhibitors or demethylase overexpression .

• ELISA testing: Quantitatively measure antibody binding to various histone peptides. For example, STJ97223 antibody has been validated to specifically detect di-methylated K10 without cross-reactivity to mono-methylated or tri-methylated forms .

• Knockout/knockdown controls: Use genetic models where the enzymes responsible for K10 di-methylation are depleted.

What applications are Di-Methyl-Histone H3 (K10) antibodies validated for?

Di-Methyl-Histone H3 (K10) antibodies have been validated for multiple research applications:

Unlike their K9 counterparts, K10 antibodies are less commonly validated for Chromatin Immunoprecipitation (ChIP), though this application may be possible with optimization .

What is the recommended protocol for Western blotting with Di-Methyl-Histone H3 (K10) antibody?

For optimal Western blot results:

• Sample preparation:

  • Extract histones using specialized acid extraction methods to enrich for histone proteins

  • Load 10-20 μg of nuclear lysate or 0.5-1 μg of purified histones

• Gel electrophoresis:

  • Use 15-18% SDS-PAGE gels to resolve the low molecular weight histone proteins

  • Include positive controls (cell lines known to have H3K10 di-methylation)

• Transfer and blocking:

  • Transfer to PVDF membrane (preferred over nitrocellulose for small proteins)

  • Block with 5% non-fat dry milk in TBST

• Antibody incubation:

  • Primary antibody: Di-Methyl-Histone H3 (K10) at 1:500-1:2000 dilution

  • Incubate overnight at 4°C

  • Secondary antibody: Anti-rabbit IgG HRP conjugate at 1:5000-1:10000

• Detection:

  • Develop using ECL substrate

  • Expected band size: 17 kDa

How should I optimize immunofluorescence experiments with Di-Methyl-Histone H3 (K10) antibody?

For successful immunofluorescence:

• Cell preparation:

  • Fix cells with 4% paraformaldehyde for 10-15 minutes

  • Permeabilize with 0.1-0.5% Triton X-100 for 5-10 minutes

  • Critical step: Include antigen retrieval if using fixed tissues

• Blocking and antibody incubation:

  • Block with 1-5% BSA, 10% normal serum, and 0.3M glycine in PBS-Tween

  • Use Di-Methyl-Histone H3 (K10) antibody at 1:50-200 dilution

  • Incubate overnight at 4°C for maximum sensitivity

• Controls to include:

  • Positive control (cell type known to express H3K10me2)

  • Negative control (primary antibody omitted)

  • Co-staining with a nuclear marker (DAPI)

• Analysis considerations:

  • H3K10me2 will show nuclear localization

  • Distribution pattern may be diffuse or punctate depending on cell type and physiological state

Why might I observe cross-reactivity with other histone modifications?

Cross-reactivity can occur for several reasons:

• Structural similarity: The amino acid sequences around K9 and K10 are similar (ARTKQTARK), making it challenging to generate highly specific antibodies .

• Antibody quality variations: Different lots or sources may have different specificity profiles. Always validate new lots with peptide arrays or dot blots .

• Experimental conditions: Certain fixation methods or buffer compositions can affect epitope accessibility and antibody binding characteristics.

To mitigate cross-reactivity:

• Use peptide competition assays to confirm specificity

• Include appropriate controls in each experiment

• Consider using orthogonal methods to confirm findings

According to peptide array data, some Di-Methyl-Histone H3 (K10) antibodies may show cross-reactivity with H3K9me2 due to the proximity of these residues .

How can I address inconsistent results between cell types or experimental conditions?

Inconsistent results may stem from:

• Biological variation in H3K10 di-methylation: Different cell types or treatments may genuinely alter the prevalence of this modification.

• Technical considerations:

  • For Western blotting: Ensure equal loading by probing for total H3 (use dedicated total H3 antibodies like clone 96C10)

  • For IHC/IF: Standardize fixation times and antigen retrieval methods

  • For ELISA: Implement standard curves and technical replicates

• Antibody-specific factors:

  • Storage conditions can affect antibody performance (store at -20°C, avoid freeze-thaw cycles)

  • Dilution buffers may need optimization (try PBS with 50% glycerol, 0.5% BSA)

Recommendation: Create a standardized experimental workflow, document all variables, and include appropriate controls specific to your experimental system.

How does di-methylation at K10 compare functionally with other histone H3 modifications?

Research suggests functional relationships between different histone modifications:

Current research indicates that different histone methyltransferases and demethylases regulate these modifications, creating a complex regulatory network. The specific enzymes responsible for H3K10 di-methylation are less well-characterized than those for H3K9 .

What experimental designs can reveal the dynamics of H3K10 di-methylation during cellular processes?

To investigate dynamic changes in H3K10 di-methylation:

• Time-course experiments:

  • Synchronize cells and collect samples at defined time points

  • Quantify H3K10me2 levels by Western blot, normalizing to total H3

  • Visualize by immunofluorescence to determine nuclear distribution changes

• ChIP-seq approaches:

  • Perform chromatin immunoprecipitation with Di-Methyl-Histone H3 (K10) antibody followed by deep sequencing

  • Map genome-wide distribution of H3K10me2

  • Compare with other histone marks and transcriptome data

• Live-cell imaging:

  • Generate cell lines expressing fluorescent readers of H3K10me2

  • Monitor real-time changes in response to stimuli

• Mass spectrometry:

  • Quantitative proteomic approaches to measure absolute levels of H3K10me2

  • Can detect combinatorial modifications on the same histone tail

What is the current understanding of histone H3K10 di-methylation in disease contexts?

While H3K9 methylation has been extensively studied in disease contexts, research on H3K10 di-methylation is emerging:

• Cancer biology:

  • Altered H3K10 methylation patterns have been observed in some cancer types

  • May function as part of broader epigenetic reprogramming during oncogenesis

• Neurodegenerative diseases:

  • Emerging evidence for altered histone methylation patterns, including at non-canonical sites

  • Changes in H3K10me2 distribution may correlate with gene expression changes in affected tissues

• Developmental disorders:

  • Mutations in histone modifying enzymes that affect H3K10 methylation may contribute to developmental abnormalities

More research is needed to establish direct causal relationships between H3K10 di-methylation and specific pathological processes. Researchers should design studies that distinguish effects of H3K10 methylation from the more extensively characterized H3K9 methylation .

What considerations are important when selecting between different commercial Di-Methyl-Histone H3 (K10) antibodies?

When choosing between available antibodies:

• Validation status:

  • Look for antibodies with comprehensive specificity testing (peptide arrays, dot blots)

  • Consider antibodies cited in peer-reviewed literature

• Application compatibility:

  • Ensure validation for your specific application (WB, IF, IHC, ChIP)

  • Check recommended dilutions and protocols

• Species reactivity:

  • Confirm reactivity with your experimental model species

  • Many antibodies react with human, mouse and rat H3K10me2

• Clone type:

  • Polyclonal antibodies may offer higher sensitivity but batch variation

  • Monoclonal antibodies provide consistency between experiments

• Technical support:

  • Consider vendors that provide detailed protocols and troubleshooting guidance

  • Some suppliers offer validation data against other methylation states

Remember that even with vendor validation, it is best practice to conduct your own validation experiments in your specific experimental system.

How do results from different detection methods for H3K10 di-methylation compare?

Different methods provide complementary information: